+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Macrocycles: Discovery, Development & Technologies

  • ID: 3068121
  • Report
  • September 2013
  • Region: Global
  • 111 Pages
  • Insight Pharma Reports
This report covers background material including a more in depth analysis of what macrocycles are and the pharmacokinetic properties (absorption, distribution, metabolism, and excretion) they exhibit. Challenges, benefits, and additional properties that are considered with their development as drugs are covered as well. Additionally, this report details specifics in technologies and current research in development.

Report Highlights:

- Expert Interviews with Bicycle Therapeutics, Encycle Therapeutics, Ensemble Therapeutics, Lanthio Pharma, Oncodesign, Pepscan, PeptiDream, RA Pharmaceuticals, Tranzyme, Pharmaceuticals and Aileron Therapeutics.

- Also exclusive to this report is a survey conducted by Insight Pharma Reports. This survey includes over 90 participants from the various organizations including academic and government institutions, pharmaceutical companies, and biotechnology companies.

- In depth analysis of what macrocycles are and the pharmacokinetic properties they exhibit.

- Reviews specifics in technologies and current research in development.

- Detailed descriptions of company overviews, technology platforms, benefits, challenges, competitive advantages, partnerships and future aspirations.

Note: Product cover images may vary from those shown
Executive Summary

Chapter 1: What are macrocycles?

Chapter 2: How Important are Pharmacokinetic Properties?

2.1 Absorption
2.2 Distribution
2.3 Metabolism
2.4 Excretion
2.5 Challenges in reaching pharmacokinetic requirements
2.5.1 Plasma concentrations
2.5.2 Drug-drug interactions
2.5.3 Drug dose administration
2.5.4 Drug absorption design Cell permeability Oral bioavailability

Chapter 3: Bicycle Therapeutics

3.1 Company Background
3.2 Cyclization chemistry platform
3.3 Benefits to the cyclization chemistry platform
3.4 Challenges and areas of improvement
3.5 Interview with Rolf Guenther and Christophe Bonny
3.6.1 Company background
3.6.2 Cyclization chemistry platform
3.6.3 Macrocyclic properties
3.6.4 Partnerships and future aspirations

Chapter 4: Encycle Therapeutics

4.1 Company background
4.2 Chemical technology platform
4.3 Partnerships, competitive advantage, and future outlook
4.4 Interview with Jeffery Coull
4.4.1 Company background
4.4.2 Chemical technology platform
4.4.3 Tracking and properties of macrocycles
4.4.4 Partnerships and future aspirations

Chapter 5: Ensemble therapeutics

5.1 Company background
5.2 DNA-programmed chemistry platform
5.2.1 Benefits to DNA-programmed chemistry platform
5.2.2 Challenges to DNA-programmed chemistry platform
5.3 Competitive advantage
5.4 Partnerships and future growth
5.5 Interview with Nick Terrett
5.5.1 Company background
5.5.2 Macrocycle background and goals
5.5.3 Macrocyclic creations and properties
5.5.4 DNA-programmed chemistry platform
5.5.5 Macrocyclic structures and expected interactions
5.5.6 Challenges and properties in macrocyclic development
5.5.7 Partnerships and future aspirations

Chapter 6: Lanthio Pharma

6.1 Company background
6.2 Lactococcus lactics platform
6.3 Benefits to Lactococcus lactis platform
6.4 Challenges encountered
6.5 Competitive advantage
6.6 Partnerships and future growth
6.7 Interview with Gert Moll
6.7.1 Company background
6.7.2 Lactococcus lactis platform
6.7.3 Macrocyclic properties
6.7.4 Challenges encountered
6.7.5 Competitive advantage
6.7.6 Partnerships and future aspirations

Chapter 7: Oncodesign Biotechnology

7.1 Company Background
7.2 Platforms developed
7.3 Nanocyclix platform
7.4 Benefits of Nanocyclix platform
7.5 Challenges encountered
7.6 Competitive advantage
7.7 Partnerships and future growth
7.8 Interview with Jan Hoflack
7.7.1 Company background
7.7.2 Nanocyclix platform
7.7.3 Nanocyclix properties
7.7.4 Partnerships and future aspirations

Chapter 8: Pepscan Therapeutics

8.1 Company background
8.2 Chemical linkage of peptides onto scaffolds (CLIPS) platform
8.3 Benefits of the CLIPS platform
8.4 Challenges of the CLIPS platform
8.5 Competitive advantage
8.6 Partnerships and future aspirations
8.7 Interview with Peter Timmerman
8.7.1 Company background
8.7.2 CLIPS platform
8.7.3 Macrocyclic properties
8.7.4 Partnerships and future aspirations

Chapter 9: PeptiDream Incorporation

9.1 Company background
9.2 Peptide discovery platform system (PDPS)
9.3 Challenges to PDPS and macrocyclic creations
9.4 Competitive advantage, partnerships, and future aspirations
9.5 Interview with Patrick Reid
9.5.1 Company background
9.5.2 PDPS platform
9.5.3 Macrocyclic properties
9.5.4 Challenges encountered
9.5.5 Competitive advantage
9.5.6 Partnerships and future aspirations

Chapter 10: Ra Pharmaceuticals

10.1 Company background
10.2 Translation platform and macrocyclic creations
10.3 Challenges encountered
10.4 Competitive advantage, partnerships, and future aspirations
10.5 Interview with Doug Treco
10.5.1 Company background
10.5.2 In vitro translation platform
10.5.3 Macrocycle tracking, creations, and properties
10.5.4 Challenges encountered
10.5.5 Partnerships and future aspirations

Chapter 11: Tranzyme Pharmaceuticals

11.1 Company background
11.2 Macrocyclic template chemistry (MATCH) platform
11.3 Benefits and competitive advantages to MATCH platform
11.4 Areas of improvement to the MATCH platform
11.5 Partnerships and future aspirations
11.6 Interview with Mark L. Peterson
11.6.1 Company background
11.6.2 Macrocyclic properties
11.6.3 MATCH platform
11.6.4 Parthersnips and future aspirations

Chapter 12: Aileron Therapeutics

12.1 Company background
12.2 Stapled Peptide platform
12.3 Competitive advantage
12.4 Areas of improvement
12.5 Partnerships and future aspirations
12.6 Interview with Vincent Guerlavais
12.6.1 Company background
12.6.2 Stapled Peptide platform
12.6.3 Macrocyclic creations and properties
12.6.4 Competitive advantage

Chapter 13: Why Macrocycles?

13.1 What improvements do macrocycles exhibit over conventional small molecules?
13.1.1 Structural modifications
13.1.2 Structural stability
13.1.3 Cell permeability, molecular activity, and half-life
13.1.4 Protein-protein interactions
13.1.5 Higher binding affinity
13.1.6 Improved binding modes
13.2 Therapeutic applications
13.3 Challenges encountered
13.4 Who’s working with macrocycles?

Note: Product cover images may vary from those shown